News Breaks |
|
|
| March 3, 2013 |
| 13:38 EDT |  | BMY, BIIB, SHPG | Unclear if pipeline alone can restore Bristol's growth, WSJ says
With Bristol-Myers' (BMY) losing Plavix patent exclusivity, the company took a 17% hit in revenues in 2012, and is now counting on new drugs like Eliquis and late-stage drugs aiming to treat cancer, diabetes and hepatitis C to restore growth, says the Wall Street Journal. However, "it remains unclear whether new drugs alone will be enough to restore growth," says WSJ, adding that in recent months Bristol has studied the possibility of Biogen Idec (BIIB) Shire (SHPG) as possible acquisition targets. Reference Link |
|
|
News For BMY;SHPG;BIIB From The Last 14 Days Check below for free stories on BMY;SHPG;BIIB the last two weeks. |
|
|
| May 24, 2013 |
| 07:20 EDT |  | BIIB | Celgene, Gilead, and Biogen could go much higher, says Bernstein
 Subscribe for More Information |
|
| May 23, 2013 |
| 08:04 EDT |  | BIIB | Biogen appoints Spyros Artavanis-Tsakonas as Chief Scientific Officer
Subscribe for More Information |
|
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT | | BMY | Stocks with implied volatility movement; SKS BMY
Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | BMY | Options Update; May 22, 2013
Subscribe for More Information |
|
| 10:33 EDT | | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
| |
| 07:24 EDT | | BIIB, BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| 05:44 EDT | | BIIB | Biogen submits application to FDA for approval of Plegridy in RMS
Subscribe for More Information |
|
| May 20, 2013 |
| 15:57 EDT | | BIIB | Biogen IMS numbers should not be adjusted down at ISI Group
ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. |
|
| 10:03 EDT | | SHPG, BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 07:39 EDT | | BIIB | Biogen weekly MS drug scripts up 26.5%, says Citigroup
Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. |
|
| 07:27 EDT | | SHPG | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| 07:01 EDT | | SHPG | Sangamo BioSciences announces positive data for Vivo Protein platform
Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach. |
|
| 06:30 EDT | | BMY, SHPG | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY, SHPG | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
| |
|
|
|
|
